# MolecularMD

Source: https://onco.cc/companies/molecularmd/  
OnCo record `molecularmd` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Portland molecular diagnostics laboratory, owned by ICON plc since 2019, that holds the FDA clearance for the MRDx BCR-ABL test in chronic myeloid leukaemia.

## Summary

MolecularMD Corporation, the applicant at Portland, Oregon on the FDA 510(k) record, holds the clearance for the MRDx BCR-ABL Test (K173492, 22 December 2017), listed by the FDA as the companion diagnostic for nilotinib in chronic myeloid leukaemia. ICON plc announced on 21 February 2019 that it had acquired MolecularMD, which it described as a molecular diagnostic specialty laboratory founded in 2006.

## Fields

- Kind: Company
- Last checked: 2026-11-03
- Also known as: MolecularMD Corporation; Molecularmd Corporation
- HQ: Portland, OR
- Type: diagnostics

## Sources

- FDA 510(k) K173492: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K173492
- ICON acquires MolecularMD (21 February 2019): https://www.iconplc.com/news-events/press-releases/icon-acquires-molecularmd

## Connected records

- cancers: [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Companion diagnostics](https://onco.cc/technologies/companion-diagnostic/)
- drugs: [MRDx BCR-ABL Test](https://onco.cc/drugs/mrdx-bcr-abl/)
- companies: [ICON plc](https://onco.cc/companies/icon-plc/)

---
JSON: https://onco.cc/api/v1/entities/molecularmd.json